Cargando…
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633639/ https://www.ncbi.nlm.nih.gov/pubmed/36329025 http://dx.doi.org/10.1038/s41408-022-00744-z |
| _version_ | 1784824278837886976 |
|---|---|
| author | Komrokji, Rami S. Singh, Avani M. Ali, Najla Al Chan, Onyee Padron, Eric Sweet, Kendra Kuykendall, Andrew Lancet, Jeffrey E. Sallman, David A. |
| author_facet | Komrokji, Rami S. Singh, Avani M. Ali, Najla Al Chan, Onyee Padron, Eric Sweet, Kendra Kuykendall, Andrew Lancet, Jeffrey E. Sallman, David A. |
| author_sort | Komrokji, Rami S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9633639 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96336392022-11-05 Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome Komrokji, Rami S. Singh, Avani M. Ali, Najla Al Chan, Onyee Padron, Eric Sweet, Kendra Kuykendall, Andrew Lancet, Jeffrey E. Sallman, David A. Blood Cancer J Correspondence Nature Publishing Group UK 2022-11-04 /pmc/articles/PMC9633639/ /pubmed/36329025 http://dx.doi.org/10.1038/s41408-022-00744-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Komrokji, Rami S. Singh, Avani M. Ali, Najla Al Chan, Onyee Padron, Eric Sweet, Kendra Kuykendall, Andrew Lancet, Jeffrey E. Sallman, David A. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_full | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_fullStr | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_full_unstemmed | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_short | Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| title_sort | assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633639/ https://www.ncbi.nlm.nih.gov/pubmed/36329025 http://dx.doi.org/10.1038/s41408-022-00744-z |
| work_keys_str_mv | AT komrokjiramis assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT singhavanim assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT alinajlaal assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT chanonyee assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT padroneric assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT sweetkendra assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT kuykendallandrew assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT lancetjeffreye assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome AT sallmandavida assessingtheroleofvenetoclaxincombinationwithhypomethylatingagentsinhigherriskmyelodysplasticsyndrome |